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Autoimmune neuropathies with autoantibodies against paranodal proteins have been described in the last few years. They comprise a subgroup of inflammatory neuropathies with IgG4 autoantibodies against the paranodal proteins neurofascin-155, contactin-1 and caspr-1. Although this subtype of autoimmune neuropathy represents less than 10 % of all patients diagnosed with CIDP, it is of high interest as they show a different response to treatment. Even though there are no therapeutic studies available due to the limited number of patients identified so far, all case reports published so far report an excellent response to treatment with rituximab, and in most cases no response to treatment with IVIG, the standard therapy of CIDP. The typical clinical picture of patients with autoantibodies against paranodal proteins is characterized by an acute onset of a severe predominantly motor neuropathy, often accompanied by action tremor and sensory ataxia, with demyelinating features in the nerve conduction studies but an axonal histological phenotype. The latter may be explained by the pathogenetic concept of a paranodopathy/nodopathy, a disease of the paranode/node of Ranvier.
Although the 2 isoforms differ only slightly, isotype-specific autoantibodies are present in almost all patients [17] . A uniform clinical phenotype, consisting of severe motor symptoms, acute onset, poor response to intravenous immunoglobulins (IVIG) and cerebellar tremor, was reported by Querol et al. [20] . This clinical phenotype was confirmed in follow-up studies [21, 22] . Neurofascin-155 autoantibodies have also been described in patients with CIDP in combination with a central involvement, but there are contradictory findings with regard to a preferential occurrence of neurofascin-155 autoantibodies in this subgroup [23, 24] . The prevalence of neurofascin-155 autoantibodies in patients with CIDP was approximately 4 % [20] in a European cohort, 3 % in a cohort with Japanese and European patients, and 7 % in Japanese cohorts [21] and 18 % [22] . The extent to which ethnic differences and a different sensitivity and specificity of the different assays play a role currently cannot be determined with certainty. However, it can be assumed that neurofascin-155 autoantibodies occur in a subgroup of patients diagnosed with a CIDP and are associated with a characteristic phenotype.
Contactin-1 Autoantibody
In 2013, Querol et al. detected autoantibodies to contactin-1 in 2 patients with CIDP, and autoantibodies to the protein complex of contactin-1 and Caspr in a further patient [16] . Clinically, the patients were characterized by acute onset severe polyneuropathy, predominantly motor in character. A study carried out in our clinic found that in 3 out of 4 patients identified with contactin-1 autoantibodies also exhibited intention tremor [25] whereas in a Japanese cohort, sensory ataxia was clinically important [26] . The prevalence in the cohorts studied so far is 2.4-7.5 % [16, 25, 26] .
Caspr-1 Autoantibody
We recently identified in our cohort of patients with inflammatory neuropathies autoantibodies to the third paranodal protein Caspr-1 [27] . While neurofascin-155 and contactin-1 autoantibodies were almost exclusively detectable in patients with chronic inflammatory polyneuropathy, Caspr-1 autoantibodies were detected in a patient with Guillain-Barré syndrome and a patient with CIDP. Both exhibited severe, acutely onset polyneuropathy, predominantly motor, and with pronounced neuropathic pain. The prevalence in our cohort was 3.5 %, but both prevalence and clinical phenotype must be confirmed in further studies (▶table 1).
Assays for the detection of autoantibodies to paranodal proteins
So far, various assays have been used for the detection of autoantibodies to paranodal proteins. The ELISA was predominantly used as a screening instrument [17, 25, 26] . However, the selection of the protein has to be taken into account: For neurofascin-155 it has been shown in several studies that the use of neurofascin-155-NS0 of the rat can result in a nonspecific binding [17, 28, 29] . Therefore, coating the ELISA plates with human neurofascin-155 is recommended. Another frequently used test is the binding experiment with HEK293 cells transfected with the DNA of the respective antigen, also in combination with flow cytometry for quantification [16, 17, 27] . For detection of the paranodal binding, binding assays were carried out with murine teased fibers in almost all studies [16, 20, 25, 27] . Thus, although with these experiments the specific antigen cannot be determined, a paranodal binding can be demonstrated. Western blot was only used in a few studies and showed false-negative results in individual patients, possibly due to the denaturation of the protein [25, 29] . In summary, the ELISA appears to be a reliable screening tool, and binding experiments with transfected HEK293 cells, or directly with the nerve tissue, are suitable as confirmatory tests.
Pathophysiology: Concept of Paranodopathy
Although neuropathies with autoantibodies to paranodal proteins are classified as subtypes of CIDP, it is not a classical demyelinating polyneuropathy. In contrast to the CIDP, in nerve biopsies, there are no signs of demyelination/remyelination, such as onion bulb formations or thinly myelinated fibers (22, 25, 27) . This is because the myelin sheath is not the point of attack of the autoantibodies. Electrophysiologically, there are conduction blocks, prolonged F-latencies and distal motor latencies, and reduced nerve conduction velocity, so that the electrophysiological criteria of a CIDP are usu-ally met [16, 20, 25, 27] . This apparent discrepancy between histology and electrophysiology is explained by the concept of paranodopathy/nodopathy, a disease targeting the complex nodal region [30, 31] . The hypothesis is that the autoantibodies interfere with the adhesion of the paranodal proteins and thus interfere with the connection between axon and myelin sheath, which could lead to elongation of the nerve and dispersion of ion channels at the node of Ranvier of the elongated nerve. Thus, the presence of conduction blocks and the extended distal motor latency can be explained by the lengthening of the myelin sheath gaps as well as the reduced nerve conduction velocity [31] . In fact, it was shown in vitro that autoantibodies to contactin-1 inhibit the adhesion of the paranodal proteins and lead to the destruction of their architecture [32] . The latter was confirmed in skin nerves and nerve teased nerve fibers of patients with contactin-1, Caspr-1, and neurofascin-155-associated neuropathy [22, 25, 27] (▶ Fig. 2) . 
Role of IgG subclasses
In the majority of cases, autoantibodies to paranodal proteins are immunoglobulins of subclass IgG4 [17, 20, [25] [26] [27] . This has a special role among the immunoglobulins in that it does not activate complement and is predominantly functionally monovalent and thus does not lead to cross-linking of antigens [33, 34] . Therefore, in the majority of patients, one cannot assume the presence of a complement-mediated inflammatory reaction, which is pathogenically relevant in neuropathies with ganglioside autoantibodies. A possible pathophysiological mechanism, however, is antibody binding-induced transformational processes in the node of Ranvier, as described above. It is assumed that the lack of efficacy for IVIG in these patients is associated with the lack of complement activation [20] . It is known that IVIG inhibits complement activation even if the exact mode of IVIG action is still not elucidated in detail [35, 36] . However, not all autoantibodies to paranodal proteins belong to the IgG4 subclass. Patients with contactin-1 and Caspr autoantibodies with IgG3 predominance have also been described. Also, most patients with predominant IgG4 autoantibodies are by no means exclusively IgG4. Thus, it was shown that sera from patients with predominant IgG4 lead to a complement binding, presumably by IgG3, though not abundantly present [37] . The extent to which IgG3 autoantibodies are pathogenic remains to be clarified in vivo. For IgG4 autoantibodies to contactin-1, a potential pathogenicity has already been demonstrated in the passive transfer model, but not yet for IgG3 [38] . The cause for the presence of different IgG subclasses with the same antigen is not yet known.
Therapy of neuropathy with antibodies to paranodal antibodies
The number of patients known to have autoantibodies to paranodal proteins is just as small as the number of studies. It is not surprising that there are no studies as yet on therapeutic strategies. However, in the available case reports, impressive and unifrom response to rituximab of patients with IgG4 autoantibodies against neurofascin-155, contactin-1 and Caspr is described [25, 27, 39] . A temporary response to corticosteroids and plasmapheresis has also also been reported, and occasionally in patients with IgG3 autoantibodies also response to IVIG [25, 27, 37] . However, the clearest and most sustained improvement is seen after administration of rituximab, so that in patients with IgG4 autoantibodies to paranodal antigens, contrary to the guidelines for CIDP therapy, this can well be the first choice drug. The extent to which this is also true of the rare occurrence of predominantly IgG3 autoantibodies to paranodal proteins cannot as yet be estimated. In patients with relatively acute onset of predominantly motor inflammatory neuropathy, the presence of autoantibodies to paranodal proteins should be suspected, especially in the case of poor response to IVIG. If there is evidence for the presence of autoantibody, given available evidence, we consider initiation of therapy with rituximab as reasonable.
Commercial tests for the detection of autoantibodies to paranodal proteins are not currently available, but research labs (for example, Würzburg University Hospital, Neurology) can help demonstrate the presence of these antibodies.
Conclusion
Neuropathies with autoantibodies to paranodal proteins are a new subgroup of immune neuropathies. The characteristic clinical picture is a relatively acute onset of severe motor neuropathy, partly together with cerebellar tremor. The autoantibodies predominantly belong to the subclass IgG4 and patients typically respond well to therapy with rituximab but most often not to IVIG.
